Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Forte Biosciences, Inc. (NASDAQ: FBRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Forte is a clinical-stage biopharmaceutical company focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases, and its filings document key financial, clinical and corporate developments around this program.
Through forms such as 10-Q and 8-K, Forte reports its quarterly financial results, including research and development expenses tied to FB102 clinical and manufacturing activities, general and administrative costs, and net loss figures. Current reports on Form 8-K also disclose material events such as positive phase 1b data in celiac disease, the initiation and status of clinical trials, and the filing of related investor presentations.
Forte’s filings further describe capital markets transactions, including an underwriting agreement for a public offering of common stock and pre-funded warrants. In these documents, the company outlines the number of shares and pre-funded warrants offered, expected gross and net proceeds, use of proceeds for working capital and FB102 development, and the terms and limitations associated with the pre-funded warrants.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight the main points from lengthy documents, helping readers quickly understand the implications of Forte’s 10-Qs, 8-Ks and other filings. Real-time updates from the EDGAR system, along with organized access to financial reports and material event disclosures, allow investors and researchers to review Forte Biosciences’ regulatory history and ongoing obligations as a Nasdaq-listed, clinical-stage biopharmaceutical company.
Forte Biosciences, Inc. chief financial officer Antony A. Riley exercised restricted stock units that converted into 375 shares of Common Stock on April 1, 2026. These RSUs had a conversion price of $0.00 per share, reflecting equity compensation rather than an open-market purchase.
To cover tax obligations from the vesting, 134 Common Shares were withheld at $24.86 per share, which is treated as a tax-withholding disposition rather than a traditional stock sale. After these transactions, Riley directly held 41,982 Common Shares and 1,125 RSUs, representing ongoing equity exposure to the company.
Forte Biosciences, Inc. director and officer Paul A. Wagner reported routine equity compensation activity. On April 1, 2026, 1,250 restricted stock units vested and were exercised into an equal number of common shares at a stated price of $0.00 per share.
To cover tax obligations on this vesting, 98 common shares were withheld at $24.86 per share, a non-market tax-withholding disposition rather than an open-market sale. After these transactions, Wagner directly holds 84,330 common shares and 3,750 RSUs, reflecting a net increase in his equity position.
The RSUs vest in installments, with one-sixteenth of the award vesting on each Quarterly Vesting Date—January 1, April 1, July 1, and October 1—under the company’s 2021 Equity Incentive Plan, so similar compensation-related transactions may continue as future tranches vest.
Forte Biosciences reported a larger 2025 net loss as it ramped investment in lead drug FB102. Net loss was $69.4 million versus $35.5 million in 2024, or $(4.71) per share versus $(12.17).
Research and development expenses rose to $58.2 million from $21.2 million, mainly from FB102 phase 2 celiac and phase 1b vitiligo and alopecia trials. General and administrative expenses declined to $12.4 million from $15.4 million, helped by lower professional and legal costs.
Forte ended 2025 with $77.0 million in cash and cash equivalents. As of December 31, 2025, there were 12.9 million common shares and 4.9 million prefunded warrants outstanding. The company highlighted multiple FB102 clinical readouts expected in 2026 across celiac disease, vitiligo and alopecia areata.
Forte Biosciences, Inc. files its annual report describing progress on FB102, its lead autoimmune biologic, and its 2025 financial position. FB102, an anti-CD122 monoclonal antibody, showed positive Phase 1b celiac disease data, including statistically significant improvements in histology, T-cell markers and gluten‑induced symptoms versus placebo in a 32‑patient trial.
The company has advanced FB102 into a Phase 2 celiac disease trial and Phase 1b trials in non‑segmental vitiligo and alopecia areata, with topline data expected in 2026. Forte reported approximately $77.0 million in cash and cash equivalents as of December 31, 2025, funded largely by equity offerings totaling about $75.0 million in 2025, $53.0 million in 2024 and $25.0 million in 2023.
The company remains a clinical‑stage, single‑asset business with no approved products, reporting a 2025 net loss of $69.4 million and an accumulated deficit of $223.4 million. Management discloses substantial ongoing capital needs and extensive regulatory, competitive and operational risks typical for early‑stage biopharmaceutical companies.
Janus Henderson Group plc has disclosed a significant ownership position in Forte Biosciences, Inc. Through its investment adviser subsidiaries, it may be deemed to beneficially own 1,425,785 shares of Forte common stock, representing 11.4% of the outstanding class as of the reporting date.
The shares are held in various managed portfolios for clients, with the asset managers sharing voting and dispositive power over all 1,425,785 shares and having no sole power. The filing also notes 521,016 pre-funded warrants held in managed portfolios that cannot be exercised if doing so would push ownership above 9.99% of Forte. Dividends and sale proceeds belong to the underlying client accounts, not Janus Henderson.
Affinity Asset Advisors, LLC and Michael Cho filed an amended Schedule 13G reporting their beneficial ownership in Forte Biosciences. They beneficially own 834,964 shares of common stock, including listed call options exercisable for 22,400 shares, representing about 6.7% of the company.
The filing notes that as of December 31, 2025, they beneficially owned approximately 8.1% of Forte Biosciences, so their ownership percentage has decreased. They certify that the position is held in the ordinary course of business and not with the purpose or effect of changing or influencing control of the company.
Forte Biosciences, Inc. reported a new large shareholder disclosure. Investment entities affiliated with Point72, including Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen, filed a Schedule 13G reporting beneficial ownership of 792,976 shares of Forte Biosciences common stock, representing 6.3% of the outstanding class as of the close of business on January 16, 2026.
The shares are held by Point72 Associates, an investment fund managed by Point72 Asset Management, with shared voting and dispositive power over all 792,976 shares and no sole voting or dispositive power. The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Forte Biosciences.
Forte Biosciences reported that its Chief Financial Officer, Riley Antony A, received new equity awards effective January 12, 2026. The awards include a stock option covering 90,000 shares of common stock with an exercise price of $29.66 per share and an expiration date of January 12, 2036, and a grant of 60,000 restricted stock units (RSUs).
The option vests monthly, with one forty-eighth of the total option shares vesting each month starting from a vesting commencement date of January 1, 2026, so that the option is fully vested after four years. The RSUs vest annually, with one fourth of the total RSUs vesting on each anniversary of the same January 1, 2026 vesting commencement date, resulting in full vesting over four years, assuming the CFO continues to serve as a Service Provider under the company’s 2021 Equity Incentive Plan.
Forte Biosciences, Inc. reported new equity awards to a senior executive. A Form 4 filing shows that on January 12, 2026, CEO, Secretary and Chair Paul A. Wagner received a stock option covering 270,000 shares of Forte Biosciences common stock with an exercise price of $29.66 per share. According to the vesting terms, one forty-eighth of the option vests each month after a vesting commencement date of January 1, 2026, so the option becomes fully vested after four years, as long as he continues as a service provider.
The filing also reports a grant of 180,000 restricted stock units, each representing a contingent right to receive one share of Forte Biosciences common stock. These RSUs vest in four equal annual installments on each anniversary of the same January 1, 2026 vesting commencement date, again conditioned on continued service. Following these grants, Wagner beneficially owns 270,000 stock options and 180,000 RSUs directly.
Forte Biosciences, Inc. received an updated ownership report from investor Steven Michael Oliveira and Nemean Asset Management, LLC. Together they report beneficial ownership of 300,100 shares of Forte Biosciences common stock, representing 2.4% of the outstanding class as of the event date of 01/08/2026. Voting and disposition power over these shares is reported as shared rather than sole.
The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Forte Biosciences, and that they are not participating in any control-related transaction.